Should FDA Require Drug Manufacturers to Test Effects of New Drugs on Varying Populations?

January 4, 2011 | Human Capital Blog Post

RWJF Scholars in Health Policy Research National Program Director Alan B. Cohen, Sc.D., had a letter in the December 29, 2010 New York Times (Avastin: Judging the Risks vs. Benefits), noting that Food & Drug Administration (FDA) approval of new drug ...